PT  - JOURNAL ARTICLE
AU  - Fox, TA
AU  - Kirkwood, AA
AU  - Enfield, L
AU  - O’Reilly, M
AU  - Arulogun, S
AU  - D’Sa, S
AU  - O’Nions, J
AU  - Kavi, J
AU  - Vitsaras, E
AU  - Townsend, W
AU  - Burns, SO
AU  - Gohil, SH
AU  - Cwynarski, K
AU  - Thomson, KJ
AU  - Noursadeghi, M
AU  - Heyderman, RS
AU  - Rampling, T
AU  - Ardeshna, KM
AU  - McCoy, LE
AU  - Morris, EC
TI  - Low seropositivity and sub-optimal neutralisation rates in patients fully vaccinated against COVID-19 with B cell malignancies
AID  - 10.1101/2021.07.19.21260762
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.19.21260762
4099  - http://medrxiv.org/content/early/2021/07/19/2021.07.19.21260762.short
4100  - http://medrxiv.org/content/early/2021/07/19/2021.07.19.21260762.full
AB  - Patients with haematological malignancies are at increased risk of severe disease and death from COVID-19 and are less likely to mount humoral immune responses to COVID-19 vaccination, with the B cell malignancies a particularly high-risk group.Our COV-VACC study is evaluating the immune response to COVID-19 vaccination in patients with B cell malignancies. Eligible patients were either receiving active treatment or had received treatment within the last 24 months. Patients were vaccinated with either the BNT162b2 (Pfizer-BioNTech) (n=41) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) (n=14) vaccines. The median age of participants was 60 years (range: 27-82) and 50% were receiving systemic anti-cancer therapy (SACT) at the time of vaccination. This interim analysis from the first 55 participants describes anti-S seropositivity rates, neutralising antibody activity and association with peripheral lymphocyte subsets.After the first vaccine dose, 36% overall had detectable anti-S antibodies rising to 42% after the second dose. Sera from seropositive patients was assessed for neutralisation activity in vitro. Of the seropositive patients after first dose (n=17), only 41% were able to neutralise SARS-CoV-2 pseudotyped virus with a 50% inhibitory dilution factor (ID50) of >1:50. After two doses (n=21) 57% of the seropositive patients had detectable neutralisation activity (median ID50 of 1:469, range 1:70 – 1:3056). Total blood lymphocyte, CD19, CD4 and CD56 counts were significantly associated with seropositivity. Patients vaccinated more than 6 months after completing therapy were significantly more likely to develop antibodies than those within 6 months of treatment or on active treatment; OR: 5.93 (1.29 – 27.28).Our data has important implications for patients with B cell malignancies as we demonstrate a disconnect between anti-S seropositivity and virus neutralisation in vitro following vaccination against COVID-19.Urgent consideration should be given to revaccinating patients with B-cell malignancies after completion of anti-cancer treatment as large numbers currently remain at high risk of infection with the increasing transmission of SARS-CoV-2 in many countries.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSouth Central Berkshire B Research Ethics Committee and UK Health Research Authority approval IRAS number: 294547Funding StatementThis study is supported by the NIHR UCLH Biomedical Research Centre and Blood Cancer UK. RSH is a NIHR Senior Investigator.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:South Central Berkshire B Research Ethics Committee and UK Health Research Authority approval IRAS number: 294547All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo supplementary data submitted